CTLA4 and prostate carcinoma: The expression level of PD-1 on Tregs, similarly to the expression of CTLA4 showed a mild but progressive increase in brachytherapy-treated prostate cancer patients, reaching significantly increased levels 36 months after seed implantation compared to patients before therapy (Figure 4E).